- Home
- SELF vs IMA Comparison
SELF vs IMA Comparison
Compare SELF & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | IMA |
|---|---|---|
| Founded | 1983 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 54.8M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SELF | IMA |
|---|---|---|
| Price | $5.51 | $5.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $16.00 |
| AVG Volume (30 Days) | 29.1K | ★ 380.5K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $12,705,245.00 | N/A |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $30.83 | ★ N/A |
| Revenue Growth | ★ 1.40 | N/A |
| 52 Week Low | $4.73 | $3.94 |
| 52 Week High | $5.83 | $17.50 |
Technical Indicators
Market Signals| Indicator | SELF | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 68.13 | 51.37 |
| Support Level | $4.93 | $5.52 |
| Resistance Level | $5.62 | $7.04 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 81.58 | 40.42 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.